Journal of Rafsanjan University of Medical Sciences
مجله دانشگاه علوم پزشکی رفسنجان
JRUMS
Medical Sciences
http://journal.rums.ac.ir
69
journal69
1735-3165
2008-7268
10.66224/jrums
fa
jalali
1404
7
1
gregorian
2025
10
1
24
7
online
1
fulltext
fa
مطالعه برونتنی رهایش کورکومین از نانوحامل MOF بر پایه ساختار چارچوب فلزی آلی و اثر آن بر روی سلول سرطانی: یک مطالعه آزمایشگاهی
In Vitro Study of Curcumin Release from MOF Nanocarrier Based on Metal-Organic Framework Structure and Its Effect on Cancer Cells: A Laboratory Study
فارماكولوژي
Pharmacology
پژوهشي
Research
<span style="font-size:10pt"><span style="line-height:115%"><span style="direction:rtl"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><a name="_Hlk113374001"><b><span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:">زمینه و هدف:</span></span></span></b></a><span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:"> سرطان تخمدان یکی از بدخیمیهای تهاجمی زنان است که با درمانهای محدود و مقاومت دارویی روبهرو است. نانوحاملهای دارویی با افزایش اثربخشی و کاهش سمیت، میتوانند بهبود چشمگیری در روند درمان ایجاد کنند. هدف این مطالعه، سنتز و ارزیابی نانوذرات </span></span></span>CUR@ZIF-8<span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:"> بهمنظور افزایش پایداری، زیستفراهمی و رهایش گزینشپذیر کورکومین در درمان سرطان تخمدان بود.</span></span></span></span></span></span></span></span><br>
<span style="font-size:10pt"><span style="line-height:115%"><span style="direction:rtl"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:">مواد و روشها:</span></span></span></b><span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:"> در این مطالعه آزمایشگاهی، نانوذرات </span></span></span>CUR@ZIF-8<span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:"> به روش همرسوبی تهیه شدند و با آزمونهای </span></span></span>DLS<span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:">، </span></span></span>FE-SEM<span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:">، </span></span></span>FT-IR<span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:">، </span></span></span>UV-Vis<span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:">، </span></span></span>PL<span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:"> و </span></span></span>BET<span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:"> مشخصهیابی شدند. بررسی رهایش کورکومین در محیطهای با </span></span></span>pH<span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:"> برابر </span></span></span><span lang="FA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:">5/5</span></span></span><span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:"> و </span></span></span><span lang="FA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:">4/7</span></span></span><span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:"> انجام شد. خاصیت ضدسرطانی نانوذرات بر سلولهای </span></span></span>A-2780<span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:"> با آزمون </span></span></span>MTT<span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:"> طی </span></span></span><span lang="FA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:">۲۴</span></span></span><span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:"> ساعت بررسی شد.</span></span></span></span></span></span></span></span><br>
<span style="font-size:10pt"><span style="line-height:115%"><span style="direction:rtl"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:">یافتهها: </span></span></span></b><span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:">اندازه نانوذرات </span></span></span>ZIF-8<span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:"> و </span></span></span>CUR@ZIF-8<span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:"> بهترتیب </span></span></span><span lang="FA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:">۱۳۵</span></span></span><span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:"> و </span></span></span><span lang="FA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:">۱۹۶</span></span></span><span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:"> نانومتر بود. راندمان کپسولاسیون </span></span></span><span lang="FA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:">۷۵ درصد</span></span></span><span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:"> و میزان بارگذاری دارو </span></span></span><span lang="FA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:">۹</span></span></span> <span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:">درصد گزارش شد. در </span></span></span>pH<span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:"> اسیدی، </span></span></span><span lang="FA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:">۹۰</span></span></span> <span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:">درصد دارو رهایش یافت، در حالیکه در </span></span></span>pH<span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:"> نرمال تنها </span></span></span><span lang="FA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:">۲۵ درصد</span></span></span><span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:"> طی </span></span></span><span lang="FA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:">۱۹۶</span></span></span><span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:"> ساعت آزاد شد. نانوذرات </span></span></span>CUR@ZIF-8<span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:"> نسبت به کورکومین آزاد، اثر مهاری بیشتری بر سلولهای سرطانی نشان دادند </span></span></span><span lang="FA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:">(</span></span></span><span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:">001/0></span></span></span>P<span lang="FA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:">).</span></span></span><span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span style="font-family:"B Nazanin""></span></span></span></span></span></span></span></span><br>
<span style="font-size:10pt"><span style="line-height:115%"><span style="direction:rtl"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span lang="FA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:">نتیجهگیری: </span></span></span></b><span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:">نانوفرمولاسیون </span></span></span>CUR@ZIF-8<span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:"> با فراهمسازی رهایش کنترل شده و هدفمند کورکومین، پتانسیل بالایی در درمان سرطان تخمدان دارد و میتواند برای داروهای کممحلول نیز کاربرد داشته باشد.</span></span></span></span></span></span></span></span><br>
<span style="font-size:10pt"><span style="line-height:115%"><span style="direction:rtl"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span lang="FA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:">واژههای کلیدی:</span></span></span></b> <span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:">کورکومین، سرطان تخمدان، سیستم حساس به </span></span></span>pH<span lang="AR-SA" style="font-size:12.0pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:">، دارورسانی، نانوحامل فلزی آلی</span></span></span></span></span></span></span></span><br>
<span style="font-size:10pt"><span style="line-height:115%"><span style="direction:rtl"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><v:roundrect arcsize="0" id="Rounded_x0020_Rectangle_x0020_9" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" style="position:absolute; left:0; text-align:left; margin-left:20px; margin-top:5px; width:467.05pt; height:44.05pt; z-index:-251652608; v-text-anchor:top"> <w:wrap anchorx="margin"> </w:wrap></v:roundrect><span lang="FA" style="font-size:2.0pt"><span style="line-height:115%"><span style="font-family:"B Nazanin""></span></span></span></span></span></span></span></span><br>
<span style="font-size:10pt"><span style="line-height:115%"><span style="direction:rtl"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span lang="FA" style="font-size:1.0pt"><span style="line-height:115%"><span style="font-family:"B Nazanin""></span></span></span></b></span></span></span></span></span><br>
<span style="font-size:10pt"><span style="line-height:115%"><span style="direction:rtl"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span lang="FA" style="font-size:11.5pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:">ارجاع:</span></span></span></b> <span lang="FA" style="font-size:11.5pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:">بشیری برازنده م، تابش ه، فرزانه ف، گلکار ع. مطالعه برون تنی رهایش کورکومین از نانوحامل </span></span></span><span dir="LTR" style="font-size:11.5pt"><span style="line-height:115%">MOF</span></span><span lang="FA" style="font-size:11.5pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:"> بر پایه ساختار چارچوب فلزی آلی و اثر آن بر روی سلول سرطانی. <i>مجله دانشگاه علوم پزشکی رفسنجان</i>، سال 1404، دوره 24 شماره 7، صفحات: </span></span></span><span lang="FA" style="font-size:11.5pt"><span style="line-height:115%"><span b="" nazanin="" style="font-family:">642-629.</span></span></span><span lang="FA" style="font-size:1.0pt"><span style="line-height:115%"><span style="font-family:"B Nazanin""></span></span></span></span></span></span></span></span><br>
<span style="font-size:10pt"><span style="line-height:150%"><span style="tab-stops:-45.0pt"><span style="text-autospace:none"><span new="" roman="" style="font-family:" times=""><a name="_Hlk114425361"><b><span style="font-size:9.0pt"><span style="line-height:150%">Background and Objectives: </span></span></b></a><span style="font-size:9.0pt"><span style="line-height:150%">Ovarian cancer is one of the most aggressive malignancies in women, characterized by limited treatment options and drug resistance. Drug nanocarriers can significantly improve the treatment process by enhancing efficacy and reducing toxicity. This study aimed to synthesize and evaluate CUR@ZIF-8 nanoparticles to increase the stability, bioavailability, and selective release of curcumin for ovarian cancer treatment.</span></span></span></span></span></span></span><br>
<span style="font-size:10pt"><span style="line-height:150%"><span style="tab-stops:-45.0pt"><span style="text-autospace:none"><span new="" roman="" style="font-family:" times=""><b><span style="font-size:9.0pt"><span style="line-height:150%">Materials and Methods:</span></span></b><span style="font-size:9.0pt"><span style="line-height:150%"> In this laboratory study, CUR@ZIF-8 nanoparticles were synthesized via a co-precipitation method and characterized using DLS, FE-SEM, FT-IR, UV-Vis, PL, and BET analyses. The release of curcumin was studied at pH 5.5 and 7.4. The anticancer effect of the nanoparticles on A-2780 cells was assessed using the MTT assay over 24 hours.</span></span></span></span></span></span></span><br>
<span style="font-size:10pt"><span style="line-height:150%"><span style="tab-stops:-45.0pt"><span style="text-autospace:none"><span new="" roman="" style="font-family:" times=""><b><span style="font-size:9.0pt"><span style="line-height:150%">Results:</span></span></b><span style="font-size:9.0pt"><span style="line-height:150%"> The particle sizes of ZIF-8 and CUR@ZIF-8 were 135 nm and 196 nm, respectively. The encapsulation efficiency and drug loading were 75% and 9%, respectively. At acidic pH, 90% of the drug was released, while only 25% was released under neutral pH over 196 hours. CUR@ZIF-8 nanoparticles exhibited greater inhibitory effects on cancer cells compared to free curcumin (p<0.0001).</span></span></span></span></span></span></span><br>
<span style="font-size:10pt"><span style="line-height:150%"><span style="tab-stops:-45.0pt"><span style="text-autospace:none"><span new="" roman="" style="font-family:" times=""><b><span style="font-size:9.0pt"><span style="line-height:150%">Conclusion:</span></span></b><span style="font-size:9.0pt"><span style="line-height:150%"> The CUR@ZIF-8 nanoformulation enables controlled and targeted curcumin release and shows a high potential for ovarian cancer therapy. It may also be applicable for the delivery of poorly soluble drugs.</span></span></span></span></span></span></span><br>
<span style="font-size:10pt"><span style="line-height:150%"><span style="tab-stops:-45.0pt"><span style="text-autospace:none"><span new="" roman="" style="font-family:" times=""><b><span style="font-size:9.0pt"><span style="line-height:150%">Keywords: </span></span></b><span style="font-size:9.0pt"><span style="line-height:150%">Curcumin, Ovarian cancer, pH-sensitive system, Drug delivery, Organic metal nanocarrier</span></span></span></span></span></span></span><br>
<span style="font-size:10pt"><span style="line-height:150%"><span style="tab-stops:-45.0pt"><span style="text-autospace:none"><span new="" roman="" style="font-family:" times=""><span dir="RTL" lang="FA" style="font-size:9.0pt"><span style="line-height:150%"></span></span></span></span></span></span></span><br>
<span style="font-size:10pt"><span style="line-height:150%"><span style="tab-stops:-45.0pt"><span style="text-autospace:none"><span new="" roman="" style="font-family:" times=""><b><span style="font-size:9.0pt"><span style="line-height:150%">Funding: </span></span></b><span style="font-size:9.0pt"><span style="line-height:150%">This study was funded by the Preventative Gynecology Research Center, Shahid Beheshti University of Medical Sciences, under contract number 20-43007996-02.</span></span></span></span></span></span></span><br>
<span style="font-size:10pt"><span style="line-height:150%"><span style="tab-stops:-45.0pt"><span style="text-autospace:none"><span new="" roman="" style="font-family:" times=""><b><span style="font-size:9.0pt"><span style="line-height:150%">Conflict of interest: </span></span></b><span style="font-size:9.0pt"><span style="line-height:150%">None declared.</span></span><b><span dir="RTL" lang="FA" style="font-size:9.0pt"><span style="line-height:150%"></span></span></b></span></span></span></span></span><br>
<span style="font-size:10pt"><span style="line-height:150%"><span style="tab-stops:-45.0pt"><span style="text-autospace:none"><span new="" roman="" style="font-family:" times=""><b><span style="font-size:9.0pt"><span style="line-height:150%">Ethical considerations: </span></span></b><span style="font-size:9.0pt"><span style="line-height:150%">The Ethics Committee of Shahid Beheshti University of Medical Sciences approved the study (IR.SBMU.RETECH.REC.1402.703).</span></span></span></span></span></span></span><br>
<span style="font-size:10pt"><span style="line-height:150%"><span style="tab-stops:-45.0pt"><span style="text-autospace:none"><span new="" roman="" style="font-family:" times=""><b><span style="font-size:9.0pt"><span style="line-height:150%">Authors’ contributions:</span></span></b></span></span></span></span></span><br>
<span style="font-size:10pt"><span style="line-height:150%"><span style="tab-stops:-45.0pt"><span style="text-autospace:none"><span new="" roman="" style="font-family:" times=""><b><span style="font-size:9.0pt"><span style="line-height:150%">- Conceptualization:</span></span></b><span style="font-size:9.0pt"><span style="line-height:150%"> Hadi Tabesh</span></span></span></span></span></span></span><br>
<span style="font-size:10pt"><span style="line-height:150%"><span style="tab-stops:-45.0pt"><span style="text-autospace:none"><span new="" roman="" style="font-family:" times=""><b><span style="font-size:9.0pt"><span style="line-height:150%">- Methodology:</span></span></b><span style="font-size:9.0pt"><span style="line-height:150%"> Mostafa Bashiri Barazandeh</span></span></span></span></span></span></span><br>
<span style="font-size:10pt"><span style="line-height:150%"><span style="tab-stops:-45.0pt"><span style="text-autospace:none"><span new="" roman="" style="font-family:" times=""><b><span style="font-size:9.0pt"><span style="line-height:150%">- Data collection:</span></span></b><span style="font-size:9.0pt"><span style="line-height:150%"> Mostafa Bashiri Barazandeh</span></span></span></span></span></span></span><br>
<span style="font-size:10pt"><span style="line-height:150%"><span style="tab-stops:-45.0pt"><span style="text-autospace:none"><span new="" roman="" style="font-family:" times=""><b><span style="font-size:9.0pt"><span style="line-height:150%">- Formal analysis:</span></span></b><span style="font-size:9.0pt"><span style="line-height:150%"> Mostafa Bashiri Barazandeh, Ali Golkar</span></span></span></span></span></span></span><br>
<span style="font-size:10pt"><span style="line-height:150%"><span style="tab-stops:-45.0pt"><span style="text-autospace:none"><span new="" roman="" style="font-family:" times=""><b><span style="font-size:9.0pt"><span style="line-height:150%">- Supervision:</span></span></b><span style="font-size:9.0pt"><span style="line-height:150%"> Hadi Tabesh, Farah Farzaneh</span></span></span></span></span></span></span><br>
<span style="font-size:10pt"><span style="line-height:150%"><span style="tab-stops:-45.0pt"><span style="text-autospace:none"><span new="" roman="" style="font-family:" times=""><b><span style="font-size:9.0pt"><span style="line-height:150%">- Project administration:</span></span></b><span style="font-size:9.0pt"><span style="line-height:150%"> Hadi Tabesh, Farah Farzaneh</span></span></span></span></span></span></span><br>
<span style="font-size:10pt"><span style="line-height:150%"><span style="tab-stops:-45.0pt"><span style="text-autospace:none"><span new="" roman="" style="font-family:" times=""><b><span style="font-size:9.0pt"><span style="line-height:150%">- Writing – original draft:</span></span></b><span style="font-size:9.0pt"><span style="line-height:150%"> Mostafa Bashiri Barazandeh</span></span></span></span></span></span></span><br>
<span style="font-size:10pt"><span style="line-height:150%"><span style="tab-stops:-45.0pt"><span style="text-autospace:none"><span new="" roman="" style="font-family:" times=""><b><span style="font-size:9.0pt"><span style="line-height:150%">- Writing – review & editing:</span></span></b><span style="font-size:9.0pt"><span style="line-height:150%"> Mostafa Bashiri Barazandeh, Ali Golkar</span></span><span style="font-size:9.0pt"><span style="line-height:150%"></span></span></span></span></span></span></span><br>
<span style="font-size:10pt"><span style="line-height:135%"><span style="tab-stops:-45.0pt"><span style="text-autospace:none"><span new="" roman="" style="font-family:" times=""><v:roundrect arcsize="0" id="Rounded_x0020_Rectangle_x0020_6" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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=
" style="position:absolute; left:0; text-align:left; margin-left:5px; margin-top:4px; width:496.3pt; height:34.95pt; z-index:251665920; v-text-anchor:top"> <v:textbox>
<table width="100%">
<tbody>
<tr>
<td>
<div><span style="font-size:10pt"><span style="line-height:150%"><span new="" roman="" style="font-family:" times=""><b><span style="font-size:8.0pt"><span style="line-height:150%">Citation: </span></span></b><span style="font-size:8.0pt"><span style="line-height:150%">Bashiri Barazandeh M, Tabesh H, Farzaneh F, Golkar A. In Vitro Study of Curcumin Release from MOF Nanocarrier Based on Metal-Organic Framework Structure and Its Effect on Cancer Cells: A Laboratory Study. <i>J Rafsanjan</i> <i>Univ Med Sci</i> 2025; 24 (7): 629-42. [Farsi]</span></span><span style="font-size:8.0pt"><span style="line-height:150%"></span></span></span></span></span></div>
</td>
</tr>
</tbody>
</table>
</v:textbox> <w:wrap anchorx="margin"> </w:wrap></v:roundrect><span style="font-size:9.0pt"><span style="line-height:135%"></span></span></span></span></span></span></span><br>
کورکومین, سرطان تخمدان, سیستم حساس به pH, دارورسانی, نانوحامل فلزی آلی
Curcumin, Ovarian cancer, pH-sensitive system, Drug delivery, Organic metal nanocarrier
629
642
http://journal.rums.ac.ir/browse.php?a_code=A-10-7033-1&slc_lang=fa&sid=1
Mostafa
Bashiri Barazandeh
مصطفی
بشیری برازنده
mostafa.bashiri@ut.ac.ir
6900319475328460061564
0009-0003-2346-0480
No
University of Tehran
دانشگاه تهران
Hadi
Tabesh
هادی
تابش
hadi.tabesh@ut.ac.ir
6900319475328460061565
6900319475328460061565
Yes
University of Tehran
دانشگاه تهران
Farah
Farzaneh
فرح
فرزانه
f_farzaneh@sbmu.ac.ir
6900319475328460061566
6900319475328460061566
No
Shahid Beheshti University of Medical Sciences
دانشگاه علوم پزشکی شهید بهشتی
Ali
Golkar
علی
گلکار
ali.golkar@ut.ac.ir
6900319475328460061567
0009-0000-8748-3698
No
University of Tehran
دانشگاه تهران